154.90 % to Target, H.C. Wainwright Maintains ‘Buy’ Rating on Inovio Pharmaceuticals (NASDAQ:INO) Shares Today

May 16, 2018 - By Nellie Frank

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Logo

Inovio Pharmaceuticals (NASDAQ:INO) Rating Reaffirmed

H.C. Wainwright now has a $13.0000 target on shares of Inovio Pharmaceuticals (NASDAQ:INO). The target means a potential upside of 154.90 % from the previous close of Inovio Pharmaceuticals (NASDAQ:INO). This rating was revealed in a research report on Wednesday morning.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 2 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $14.0 highest and $1300 lowest target. $13.50’s average target is 164.71% above currents $5.1 stock price. Inovio Pharmaceuticals had 9 analyst reports since November 28, 2017 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, March 21 report. The firm earned “Buy” rating on Thursday, March 15 by H.C. Wainwright. The firm earned “Buy” rating on Friday, January 12 by H.C. Wainwright. H.C. Wainwright maintained the shares of INO in report on Wednesday, January 3 with “Buy” rating. The company was maintained on Thursday, March 15 by RBC Capital Markets. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, February 13 report. As per Tuesday, November 28, the company rating was maintained by H.C. Wainwright. As per Thursday, April 12, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, January 23 report.

The stock increased 2.00% or $0.1 during the last trading session, reaching $5.1. About 1.45M shares traded or 42.63% up from the average. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 24.44% since May 17, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on August, 14. They expect $-0.28 earnings per share, down 115.38 % or $0.15 from last year’s $-0.13 per share. After $-0.36 actual earnings per share reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.22 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $463.91 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More important recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: Schaeffersresearch.com which released: “Inovio Stock Buzzing After HIV Vaccine Data” on May 15, 2018, also Streetinsider.com published article titled: “Inovio Pharma (INO) Says HIV Vaccine Sustained Durable Memory Responses Measured One Year After Start of …”, Globenewswire.com published: “Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results” on May 09, 2018. More interesting news about Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was released by: Nasdaq.com and their article: “Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses …” with publication date: May 15, 2018.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.